Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Jae H. Park, MD, Isabelle Riviere, PhD, Devanjan S. Sikder, Vladimir P. Bermudez, Brigitte Senechal, Xiuyan Wang, PhD, Thomas H. Auchincloss, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, M. Lia Palomba, MD, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143088

Published: 2020

Journal Articles

Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

Gee Youn (Geeny) Kim, PharmD, Jamie L. Koprivnikar, MD, Rebecca Testi, MSN, RN, APN-C, OCN, Tara McCabe, FNP-C, MSN, RN, BSN, Grace Perry, MSN, RN, APN-C, OCN, Danielle Marcotulli, MSN, RN, FNP-BC, AOCNP, Elizabeth Jones, BSN, RN, OCN, Xue Geng, MS, Ming Tan, James K. McCloskey, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-142891

Published: 2020

Journal Articles

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Julio C. Chavez, MD, Ariel F Grajales-Cruz, MD, Virginia Olivia Volpe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Eva Sahakian, PhD, Nicole Rozario, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5483.

https://doi.org/10.1182/blood-2019-132211

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Blood (2019) 134 (Supplement_1): 4455.

https://doi.org/10.1182/blood-2019-127480

Published: 2019

Journal Articles

Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management

Blood (2019) 134 (Supplement_1): 4458.

https://doi.org/10.1182/blood-2019-126022

Published: 2019

Journal Articles

Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation

Meagan V. Lew, BS, Yi Ren, MS, Yen P. Lowder, MS, RD, CNSC, Kristi M. Romero, BS, Jillian C. Thompson, MS, Lauren M. Bohannon, BS, Harvey Cohen, MD, David A. Bartlett, PhD, Amy M. Pastva, PT, PhD, Miriam Morey, PhD, Katherine Hall, PhD, Patrick Smith, PhD, Katherine B. Peters, MD PhD FAAN, Tamara Somers, PhD, Sarah Kelleher, PhD, Sophia Smith, PhD MSW, Paul Wischmeyer, MD, Pao-Hwa Lin, PhD, Glynnis Thorpe, MSN, RN, Kerry Minor, MSN, ANP-BC, Allison Adler, RN, MSN, OCN, BMTCN, Kristi Wiggins, MSN, ANP-BC, AOCNP, Therese Hennig, PA, Tanya Helms, PA-C, Renee Welch, RN, BSN, BMTCN, Whitney Hicks, RN, MSN, BMTCN, Margaret Eren, RN, FNP-BC, AOCNP, MSN, Rebecca Porter, RN, MSN, NP-C, Brittany Matthews, NP,RN, JoAnn Liu, DNP-FNP-BC, AOCNP, Jill Burleson, NP, RN, Whitney Andrew, PA-C, Thomas Aberant, PA-C, Ashley K. Engemann, PharmD, Bethany Henshall, MSW, LCSW, Maurisa Darby, LCSW, MSW, Renea Valea, LCSW, MSW, Christina Proch, RD, Michelle Dellascio, PT, DPT, Alyssa Pittman, OT, Taewoong Choi, MD, Cristina Gasparetto, MD, Gwynn D. Long, MD, Richard D. Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Mitchell E. Horwitz, MD, Nelson J. Chao, MD, Anthony D. Sung, MD

Blood (2019) 134 (Supplement_1): 1984.

https://doi.org/10.1182/blood-2019-127264

Published: 2019

Journal Articles

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Blood (2019) 134 (Supplement_1): 1947.

https://doi.org/10.1182/blood-2019-126208

Published: 2019

Journal Articles

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Jae H. Park, MD, Jessica Flynn, BS, Mithat Gonen, Yvette Bernal, MS, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2019) 134 (Supplement_1): 1348.

https://doi.org/10.1182/blood-2019-129343

Published: 2019

Journal Articles

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Hannah Asghari, MD BS, Chetasi Talati, MD, Alexandra Achille, John J. Powers, BS, Eva Sahakian, PhD, Onyee Chan, MD, Dawne N Shelton, PhD, Leidy Isenalumhe, MD, Lisa Nodzon, PhD ARNP, AOCNP, Kendra L. Sweet, MD, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 3382.

https://doi.org/10.1182/blood-2019-131207

Published: 2019

Journal Articles

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Blood (2018) 132 (Supplement 1): 959.

https://doi.org/10.1182/blood-2018-99-119717

Published: 2018

Journal Articles

Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies

Gunjan L. Shah, MDMS, Jae H. Park, MD, Craig S. Sauter, MD, Elaine Duck, RN MS MA, Elizabeth Halton, NP-BC AOCNP, Maria Lia Palomba, MD, Connie Lee Batlevi, MD, Anas Younes, MD, Mark Blaine Geyer, MD, Eric L. Smith, MD PhD, Sham Mailankody, MBBS, Elena Mead, MD, Bianca Santomasso, MD PhD, Miguel-Angel Perales, MD, Paul Sabbatini, MD, Sergio Giralt, MD, Renier J. Brentjens, MD PhD, Peter Bach, MD

Blood (2018) 132 (Supplement 1): 616.

https://doi.org/10.1182/blood-2018-99-114093

Published: 2018

Journal Articles

Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity

Blood (2018) 132 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2018-99-118628

Published: 2018

Journal Articles

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia

Ariel Felipe Grajales-Cruz, MD, Julio C. Chavez, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Francisco Perez Leal, MD, Jose Sandoval-Sus, MD, Rami S. Komrokji, MD, Frederick L. Locke, MD, Mohamed A Kharfan-Dabaja, MD, Bijal D. Shah, MD, Lubomir Sokol, MD PhD, Celeste M. Bello, MD, Javier Pinilla Ibarz, MD

Blood (2018) 132 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2018-99-111564

Published: 2018

Journal Articles

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Jae H. Park, MD, Maria Lia Palomba, MD, Connie Lee Batlevi, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Brigitte Senechal, PhD, Richard R. Furman, MD, Yvette Bernal, MS, Malloury Hall, BA, John Pineda, RN, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2018) 132 (Supplement 1): 224.

https://doi.org/10.1182/blood-2018-99-117737

Published: 2018

Journal Articles

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Najla H El Jurdi, MD, Masumi Ueda, MD MA, BA, Philip Woost, PhD, Hillard M Lazarus, MD, Paolo Caimi, MD, Brenda W. Cooper, MD, Richard Creger, PhD, Jane A. Little, MD, Linda Baer, MSN, NP-C, AOCNP, Lauren Brister, MSN, NP-C, AOCNP, Ehsan Malek, MD, Leland Metheny, MD, Folashade Otegbeye, MBBChir, MPH, Ben K. Tomlinson, MD, Basem M. William, MRCP,MD, James Jacobberger, PhD, Marcos De Lima, MD

Blood (2017) 130 (Supplement 1): 5503.

https://doi.org/10.1182/blood.V130.Suppl_1.5503.5503

Published: 2017

Journal Articles

Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)

Lisa Nodzon, PhD ARNP, AOCNP, Sara Tinsley-Vance, PhD ARNP, AOCN

Blood (2017) 130 (Supplement 1): 5624.

https://doi.org/10.1182/blood.V130.Suppl_1.5624.5624

Published: 2017

Journal Articles

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Ajay K Nooka, MD MPH, Nisha Joseph, MD, Larry H Boise, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Jonathan L. Kaufman, MD, Sagar Lonial, MD FACP

Blood (2016) 128 (22): 492.

https://doi.org/10.1182/blood.V128.22.492.492

Published: 2016

Journal Articles

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Prashanth Kumar, Nisha Joseph, MD, Dhwani Almaula, MPH, Lawrence H Boise, PhD, Jonathan L. Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Sagar Lonial, MD FACP, Ajay K Nooka, MD MPH

Blood (2016) 128 (22): 4524.

https://doi.org/10.1182/blood.V128.22.4524.4524

Published: 2016

Journal Articles

Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)

Ajay K. Nooka, MD MPH, Jonathan L. Kaufman, MD, A. Tuba Karagulle Kendi, MD, Yan Li, Chikaodili O Obidike, Charise Gleason, MSN, ANP-BC, AOCNP, Lawrence H Boise, PhD, Sagar Lonial, MD

Blood (2015) 126 (23): 4202.

https://doi.org/10.1182/blood.V126.23.4202.4202

Published: 2015

NARROW

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management

Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies

Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only